<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625404</url>
  </required_header>
  <id_info>
    <org_study_id>10015</org_study_id>
    <nct_id>NCT00625404</nct_id>
  </id_info>
  <brief_title>FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women</brief_title>
  <official_title>Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FHI 360</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase III, double-blind, randomized, placebo-controlled trial enrolled HIV-negative
      women from 4 sites in 3 countries (Kenya, Tanzania, South Africa). The study's purpose was to
      investigate the safety and effectiveness of a once-daily Truvada® pill (compared with
      placebo) in preventing HIV among HIV-uninfected women at risk of becoming infected through
      sexual intercourse.

      The study population included HIV-antibody-negative women between the ages of 18-35 who were
      at risk of HIV acquisition through sexual intercourse. Each participant was randomized to
      take either a daily single oral tablet of Truvada®, which is a fixed-dose combination of
      emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg), or an identical
      placebo.

      After enrollment, each participant was followed every four weeks. All participants were
      followed for an additional eight weeks after study drug was stopped. Incidence rates of HIV
      infection were compared between the two groups (active drug and placebo) using the
      intent-to-treat principle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase III, double-blind, randomized, placebo-controlled trial enrolled HIV-negative
      women from 4 sites in 3 countries (Kenya, Tanzania, South Africa). The study's purpose was to
      investigate the safety and effectiveness of a once-daily Truvada® pill (compared with
      placebo) in preventing HIV among HIV-uninfected women at risk of becoming infected through
      sexual intercourse.

      The study population included HIV-antibody-negative women between the ages of 18-35 who were
      at risk of HIV acquisition through sexual intercourse. Each participant was randomized to
      take either a daily single oral tablet of Truvada®, which is a fixed-dose combination of
      emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg), or an identical
      placebo. All participants received risk reduction counseling and condoms. Women had to be
      using a study-approved effective non-barrier contraceptive method at the time of enrollment
      and were asked to do so for the whole period they were on study drug. They received
      contraceptive counseling throughout the study. Any diagnosed, treatable sexually transmitted
      infection was treated free of charge.

      After enrollment, each participant was followed every four weeks. All participants were
      followed for an additional eight weeks after study drug was stopped. Participants at risk for
      Hepatitis B Virus (HBV) flare were followed every four weeks for 12 weeks after stopping
      study product. Participants who acquired HIV infection during the study stopped taking the
      study drug at the time of HIV diagnosis, and will be followed for 52 weeks post diagnosis and
      were referred for care and treatment. Participants who became pregnant stopped taking the
      study drug but continued follow-up visits. Incidence rates of HIV infection were compared
      between the two groups (active drug and placebo) using the intent-to-treat principle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Infection</measure>
    <time_frame>Cumulative HIV infection between enrollment and 52 weeks</time_frame>
    <description>HIV Seroconversion, with time to infection refined based on PCR results obtained from stored specimens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed Grade 2 or Higher Serum Creatinine Toxicity</measure>
    <time_frame>cumulative toxicity through 52 weeks of product use and 4 weeks post product</time_frame>
    <description>Repeat specimens were collected to confirm chemistry toxicities. Grade 2 or higher serum creatinine toxicity was defined as ≥1.4 times the upper limit of normal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Nature of Adverse Events (AEs) During and Within 4 Weeks After Study Product Administration</measure>
    <time_frame>10-26 months per site</time_frame>
    <description>The total number of adverse events in the placebo and Truvada arms during and within 4 weeks after study product administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed Grade 3 or Higher Reduction in Phosphorus</measure>
    <time_frame>Through 52 weeks on product and 4 weeks post-product</time_frame>
    <description>Repeat specimens were collected to confirm chemistry toxicities. Grade 3 phosphorus reduction was defined as ≤2.4mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed Grade 3 or Higher ALT Elevation</measure>
    <time_frame>Through 52 weeks on product and 4 weeks post-product</time_frame>
    <description>Grade 3 or higher ALT elevation was defined as ≥ 2.6 times the upper limit of normal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed Grade 3 or Higher AST Elevation</measure>
    <time_frame>Through 52 weeks on product and 4 weeks post-product</time_frame>
    <description>Grade 3 or higher AST elevation was defined as ≥ 2.6 times the upper limit of normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV RNA Level (HIV-1 Viral Load)</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>Viral load at the time of HIV detection, HIV conversion and through 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell Count</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>CD4+ T-cell Count at the Time of HIV Seroconversion through 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FTC and/or Tenofovir Resistance</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Genotypic resistance to FTC and/or tenofovir at the time of HIV diagnosis and 4 weeks later. If resistance was present, testing was repeated at weeks 12, 24, 36 and 52 as necessary (resistance testing will stop if no resistance is detected).
participants were classified as having resistance if they had one or more visits in which resistance was detected, even if the resistance became undetectable over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Complications</measure>
    <time_frame>up to 60 weeks</time_frame>
    <description>Reported complications during pregnancy, including spontaneous abortion, vaginal or uterine bleeding, emergency c-section and other complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pill Counts and Participant Report of Adherence to Once-daily Pill Taking</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Pill counts and participant report of adherence to once-daily pill taking reported as mean days study product could have been used according to pill counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Report of Change in Number of Sexual Partners</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Difference in mean number of reported sexual partners between final study visit and enrollment visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2120</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Truvada Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
    <arm_group_label>Truvada Arm</arm_group_label>
    <other_name>TDF/FTC - emtricitabine and tenofovir disoproxil fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able (see criterion 2) to provide written informed consent to be screened
             for and to participate in the trial

          2. Able to answer a percentage of informed consent screening (75%) and enrollment (100%)
             comprehension quiz questions correctly

          3. Between 18-35 years old, inclusive

          4. At higher risk of becoming HIV infected

          5. Have a final negative result according to the site-specific screening HIV testing
             algorithm and a final negative result at enrollment according to the study HIV testing
             algorithm

          6. Willing to participate in all aspects of the study and to comply with study
             procedures, for up to 60 weeks, including:

               -  Be randomized

               -  Use study product as directed

               -  Adhere to follow-up schedule and willing to be contacted by site staff between
                  study visits (by phone and/or in person)

               -  Use a study-approved effective non-barrier method of contraception for the
                  duration of the study

               -  Take study product, as evidenced by swallowing a vitamin tablet that is similar
                  in size to the study product at enrollment

               -  Provide contact information and agrees to some form of contact method throughout
                  the study

          7. Not intending to relocate out of the area for the duration of the study participation
             and does not have a job or other obligations that may require long absences from the
             area ( &gt; 1 month at a time)

          8. In general good health and have no condition (social or medical) which, in the opinion
             of the Site Investigator, would make study participation unsafe or complicate data
             interpretation

          9. Not pregnant or breastfeeding, and does not anticipate a desire for pregnancy during
             the 52 weeks of on-product participation

         10. Medically eligible at screening including:

               -  Adequate renal function (serum creatinine ≤ upper limit of normal (ULN) of local
                  range and creatinine clearance ≥ 60ml/min estimated by the Cockcroft-Gault
                  Creatinine Clearance Formula

               -  Adequate hepatic function (hepatic transaminases ALT and AST &lt; 2x ULN [according
                  to local normal ranges])

               -  HBsAg negative

               -  Serum phosphorus levels above the lower limit of the local normal range
                  (according to local normal ranges - grade 3 &amp; 4 hypophosphatemia will be excluded
                  even if within normal local ranges)

         11. Not received or receiving an experimental HIV vaccine, participating in another HIV
             prevention study or participating in any other clinical trial with a biomedical
             intervention

         12. No clinical signs of liver disease (e.g., ascites, spider angiomata, hepatomegaly,
             jaundice)

         13. No definite evidence of glycosuria or proteinuria (i.e., no repeated positive [ ≥ + 1
             ] urine dipstick). If a urine dipstick is positive for either glucose and/or protein
             at the first test, a second urine sample will be tested.

         14. No history of pathological bone fractures

         15. No history of adverse reaction to latex

         16. Not taking any of the following medications: nephrotoxic agents; aminoglycoside
             antibiotics (including gentamicin); intravenous (IV) amphotericin B; cidofovir;
             cisplatin; foscarnet; IV pentamidine; oral or IV vancomycin; oral or IV gancyclovir;
             other agents with significant nephrotoxic potential; drugs that slow renal excretion;
             probenecid; immune system modulators; systemic chemotherapeutic agents (i.e. cancer
             treatment medications); systemic corticosteroids; interleukin-2 (IL-2);
             immunomodulators; interferon (alpha, beta, or gamma); other antiretrovirals (including
             nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease
             inhibitors or investigational antiretroviral agents)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lut Van Damme, MD, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amy Corneli, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Deese, MPH</last_name>
    <role>Study Director</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bondo Clinic, Bondo District Hospital</name>
      <address>
        <city>Bondo</city>
        <state>Nyanza</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josha Research Center</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arusha Clinic, Levolosi Health Center</name>
      <address>
        <city>Arusha</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>South Africa</country>
    <country>Tanzania</country>
  </location_countries>
  <removed_countries>
    <country>Malawi</country>
    <country>Zimbabwe</country>
  </removed_countries>
  <link>
    <url>http://ghr.nlm.nih.gov/condition/complement-factor-i-deficiency</url>
    <description>Genetics Home Reference for complement factor I deficiency</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/hivaids.html</url>
    <description>MedlinePlus: AIDS</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/hepatitis.html</url>
    <description>MedlinePlus: Hepatitis</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0000057114&amp;QV1=N-OCTADECANOIC+ACID</url>
    <description>Drug Information: n-Octadecanoic acid</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0001592230&amp;QV1=CALCIUM+STEARATE</url>
    <description>Drug Information: Calcium stearate</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0007047849&amp;QV1=ALUMINUM+MONOSTEARATE</url>
    <description>Drug Information : Aluminum monostearate</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <link>
    <url>http://www.nejm.org/doi/full/10.1056/NEJMoa1202614</url>
    <description>Study based publication</description>
  </link>
  <results_reference>
    <citation>Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012 Aug 2;367(5):411-22. doi: 10.1056/NEJMoa1202614. Epub 2012 Jul 11.</citation>
    <PMID>22784040</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <results_first_submitted>December 9, 2013</results_first_submitted>
  <results_first_submitted_qc>March 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2014</results_first_posted>
  <last_update_submitted>March 31, 2018</last_update_submitted>
  <last_update_submitted_qc>March 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspartate Aminotransferase (AST)</keyword>
  <keyword>Alanine Aminotransferase (ALT)</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV Prevention</keyword>
  <keyword>Oral PrEP</keyword>
  <keyword>Truvada</keyword>
  <keyword>women</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>TDF</keyword>
  <keyword>FTC</keyword>
  <keyword>emtricitabine</keyword>
  <keyword>hepatitis</keyword>
  <keyword>Pre-exposure Prophylaxis (PrEP)</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Truvada Arm</title>
          <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1062"/>
                <participants group_id="P2" count="1058"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="855"/>
                <participants group_id="P2" count="885"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="173"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Truvada Arm</title>
          <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1062"/>
            <count group_id="B2" value="1058"/>
            <count group_id="B3" value="2120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1062"/>
                    <measurement group_id="B2" value="1058"/>
                    <measurement group_id="B3" value="2120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="18-35" lower_limit="18" upper_limit="35"/>
                    <measurement group_id="B2" value="23" spread="18-35" lower_limit="18" upper_limit="35"/>
                    <measurement group_id="B3" value="23" spread="18-35" lower_limit="18" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1062"/>
                    <measurement group_id="B2" value="1058"/>
                    <measurement group_id="B3" value="2120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HIV Infection</title>
        <description>HIV Seroconversion, with time to infection refined based on PCR results obtained from stored specimens.</description>
        <time_frame>Cumulative HIV infection between enrollment and 52 weeks</time_frame>
        <population>All randomized participants who made at least one follow-up visit and were not HIV-positive at enrollment were included in the analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>The effectiveness population consisted of all women who were randomized and who had at least one follow-up visit and were not HIV PCR positive at enrollment. This population consisted of 2056 women (1024 in the Truvada arm, 1032 in the placebo arm) and was used for baseline analyses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>The effectiveness population consisted of all women who were randomized and who had at least one follow-up visit and were not HIV PCR positive at enrollment. This population consisted of 2056 women (1024 in the Truvada arm, 1032 in the placebo arm) and was used for baseline analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Infection</title>
          <description>HIV Seroconversion, with time to infection refined based on PCR results obtained from stored specimens.</description>
          <population>All randomized participants who made at least one follow-up visit and were not HIV-positive at enrollment were included in the analysis population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1024"/>
                <count group_id="O2" value="1032"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="3.25" upper_limit="6.63"/>
                    <measurement group_id="O2" value="35" lower_limit="3.47" upper_limit="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio (HR) for HIV infection based on proportional hazards model, stratified on site. Study was designed to have 90% power to reject the null hypothesis that the HR for infection is &gt; 0.3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Grade 2 or Higher Serum Creatinine Toxicity</title>
        <description>Repeat specimens were collected to confirm chemistry toxicities. Grade 2 or higher serum creatinine toxicity was defined as ≥1.4 times the upper limit of normal</description>
        <time_frame>cumulative toxicity through 52 weeks of product use and 4 weeks post product</time_frame>
        <population>The Safety Population consisted of all women who were randomized and who had at least one follow-up visit and did not return all of their product un-used. Only women assessed for a particular safety outcome were included in analysis of that outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Grade 2 or Higher Serum Creatinine Toxicity</title>
          <description>Repeat specimens were collected to confirm chemistry toxicities. Grade 2 or higher serum creatinine toxicity was defined as ≥1.4 times the upper limit of normal</description>
          <population>The Safety Population consisted of all women who were randomized and who had at least one follow-up visit and did not return all of their product un-used. Only women assessed for a particular safety outcome were included in analysis of that outcome.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1021"/>
                <count group_id="O2" value="1033"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Log-rank test for difference in rate of grade 2 or higher creatinine, based on time to first event.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Nature of Adverse Events (AEs) During and Within 4 Weeks After Study Product Administration</title>
        <description>The total number of adverse events in the placebo and Truvada arms during and within 4 weeks after study product administration.</description>
        <time_frame>10-26 months per site</time_frame>
        <population>The Safety Population, a subset of the ITT Population, excludes participants who never received study product, returned all product unused, or never returned for a follow-up visit. Analyses were performed by randomly assigned treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>The Safety Population, a subset of the ITT Population, excludes participants who never received study product, returned all product unused, or never returned for a follow-up visit. Analyses were performed by randomly assigned treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>The Safety Population, a subset of the ITT Population, excludes participants who never received study product, returned all product unused, or never returned for a follow-up visit. Analyses were performed by randomly assigned treatment group.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Nature of Adverse Events (AEs) During and Within 4 Weeks After Study Product Administration</title>
          <description>The total number of adverse events in the placebo and Truvada arms during and within 4 weeks after study product administration.</description>
          <population>The Safety Population, a subset of the ITT Population, excludes participants who never received study product, returned all product unused, or never returned for a follow-up visit. Analyses were performed by randomly assigned treatment group.</population>
          <units>Number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1025"/>
                <count group_id="O2" value="1033"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2257"/>
                    <measurement group_id="O2" value="2384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Grade 3 or Higher Reduction in Phosphorus</title>
        <description>Repeat specimens were collected to confirm chemistry toxicities. Grade 3 phosphorus reduction was defined as ≤2.4mg/dL</description>
        <time_frame>Through 52 weeks on product and 4 weeks post-product</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Grade 3 or Higher Reduction in Phosphorus</title>
          <description>Repeat specimens were collected to confirm chemistry toxicities. Grade 3 phosphorus reduction was defined as ≤2.4mg/dL</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1021"/>
                <count group_id="O2" value="1033"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Log-rank test for difference in rates between groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Grade 3 or Higher ALT Elevation</title>
        <description>Grade 3 or higher ALT elevation was defined as ≥ 2.6 times the upper limit of normal</description>
        <time_frame>Through 52 weeks on product and 4 weeks post-product</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Grade 3 or Higher ALT Elevation</title>
          <description>Grade 3 or higher ALT elevation was defined as ≥ 2.6 times the upper limit of normal</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1021"/>
                <count group_id="O2" value="1033"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Log-rank test for difference in rates between groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Grade 3 or Higher AST Elevation</title>
        <description>Grade 3 or higher AST elevation was defined as ≥ 2.6 times the upper limit of normal</description>
        <time_frame>Through 52 weeks on product and 4 weeks post-product</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Grade 3 or Higher AST Elevation</title>
          <description>Grade 3 or higher AST elevation was defined as ≥ 2.6 times the upper limit of normal</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1021"/>
                <count group_id="O2" value="1033"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Log-rank test for difference in rates between groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma HIV RNA Level (HIV-1 Viral Load)</title>
        <description>Viral load at the time of HIV detection, HIV conversion and through 16 weeks</description>
        <time_frame>up to 16 weeks</time_frame>
        <population>68 women who became infected post-enrollment were included in viral load analyses. Only 48 of these women (27 on Truvada and 21 on placebo) contributed a specimen sample for analysis at the 16-weeks post seroconversion visit</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma HIV RNA Level (HIV-1 Viral Load)</title>
          <description>Viral load at the time of HIV detection, HIV conversion and through 16 weeks</description>
          <population>68 women who became infected post-enrollment were included in viral load analyses. Only 48 of these women (27 on Truvada and 21 on placebo) contributed a specimen sample for analysis at the 16-weeks post seroconversion visit</population>
          <units>log copies/mL</units>
          <param>Log Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="1.05"/>
                    <measurement group_id="O2" value="4.37" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>t-test for difference on viral loads</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T-cell Count</title>
        <description>CD4+ T-cell Count at the Time of HIV Seroconversion through 16 weeks</description>
        <time_frame>Up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell Count</title>
          <description>CD4+ T-cell Count at the Time of HIV Seroconversion through 16 weeks</description>
          <units>cells/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="579.3" spread="318.2"/>
                    <measurement group_id="O2" value="601.4" spread="318.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>t-test for difference in mean CD-4 counts</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.1</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FTC and/or Tenofovir Resistance</title>
        <description>Genotypic resistance to FTC and/or tenofovir at the time of HIV diagnosis and 4 weeks later. If resistance was present, testing was repeated at weeks 12, 24, 36 and 52 as necessary (resistance testing will stop if no resistance is detected).
participants were classified as having resistance if they had one or more visits in which resistance was detected, even if the resistance became undetectable over time.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>All women who seroconverted were assessed for possible resistance.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>FTC and/or Tenofovir Resistance</title>
          <description>Genotypic resistance to FTC and/or tenofovir at the time of HIV diagnosis and 4 weeks later. If resistance was present, testing was repeated at weeks 12, 24, 36 and 52 as necessary (resistance testing will stop if no resistance is detected).
participants were classified as having resistance if they had one or more visits in which resistance was detected, even if the resistance became undetectable over time.</description>
          <population>All women who seroconverted were assessed for possible resistance.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Complications</title>
        <description>Reported complications during pregnancy, including spontaneous abortion, vaginal or uterine bleeding, emergency c-section and other complications</description>
        <time_frame>up to 60 weeks</time_frame>
        <population>Women becoming pregnant during regular follow-up in the study (70 in Truvada group and 45 in placebo group)</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Complications</title>
          <description>Reported complications during pregnancy, including spontaneous abortion, vaginal or uterine bleeding, emergency c-section and other complications</description>
          <population>Women becoming pregnant during regular follow-up in the study (70 in Truvada group and 45 in placebo group)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pill Counts and Participant Report of Adherence to Once-daily Pill Taking</title>
        <description>Pill counts and participant report of adherence to once-daily pill taking reported as mean days study product could have been used according to pill counts</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>All randomized participants who completed at least one follow-up visit, excluding women found to have been infected at enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Pill Counts and Participant Report of Adherence to Once-daily Pill Taking</title>
          <description>Pill counts and participant report of adherence to once-daily pill taking reported as mean days study product could have been used according to pill counts</description>
          <population>All randomized participants who completed at least one follow-up visit, excluding women found to have been infected at enrollment</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1024"/>
                <count group_id="O2" value="1032"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="0.20"/>
                    <measurement group_id="O2" value="89" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Report of Change in Number of Sexual Partners</title>
        <description>Difference in mean number of reported sexual partners between final study visit and enrollment visit</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Women reporting on sexual behavior during follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Arm</title>
            <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Report of Change in Number of Sexual Partners</title>
          <description>Difference in mean number of reported sexual partners between final study visit and enrollment visit</description>
          <population>Women reporting on sexual behavior during follow-up</population>
          <units>mean number of sexual partners</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="977"/>
                <count group_id="O2" value="989"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.60" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="-0.13" spread="0.79" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>t-test for difference in change in number of sexual partners over time</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.01</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>These data are from the safety population, which is a subset of the intent to treat (ITT) population, excluding those participants found to have been HIV infected at enrollment and participants who never received study product, returned all product unused, or never returned for a follow-up visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Truvada Arm</title>
          <description>Daily single oral tablet of Truvada, a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1025"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>exomphalos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>typhoid fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>malaria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>tuberculosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>abdominal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>abortion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>ectopic pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>foetal distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>premature rupture of the membranes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>removal of foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="761" subjects_at_risk="1025"/>
                <counts group_id="E2" subjects_affected="749" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1025"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Exomphalos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Abnormal vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="52" subjects_affected="50" subjects_at_risk="1025"/>
                <counts group_id="E2" events="33" subjects_affected="32" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="1025"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="38" subjects_affected="37" subjects_at_risk="1025"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="1025"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="1025"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="1025"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1025"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="1025"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1025"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1025"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Hyperphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1025"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1025"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="1025"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pruritus allergic</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="1025"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Idiopathic urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="154" subjects_affected="123" subjects_at_risk="1025"/>
                <counts group_id="E2" events="157" subjects_affected="121" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="108" subjects_affected="96" subjects_at_risk="1025"/>
                <counts group_id="E2" events="125" subjects_affected="108" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" events="69" subjects_affected="67" subjects_at_risk="1025"/>
                <counts group_id="E2" events="81" subjects_affected="81" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="62" subjects_affected="60" subjects_at_risk="1025"/>
                <counts group_id="E2" events="57" subjects_affected="52" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="1025"/>
                <counts group_id="E2" events="39" subjects_affected="38" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="1025"/>
                <counts group_id="E2" events="38" subjects_affected="34" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="1025"/>
                <counts group_id="E2" events="42" subjects_affected="36" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="1025"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="1025"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="1025"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="1025"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1025"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="1025"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1025"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1025"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1025"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1025"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Helminthic infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Extrapulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1025"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Human bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Anthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Contusion of knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="267" subjects_affected="199" subjects_at_risk="1025"/>
                <counts group_id="E2" events="257" subjects_affected="189" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="177" subjects_affected="134" subjects_at_risk="1025"/>
                <counts group_id="E2" events="147" subjects_affected="119" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="162" subjects_affected="119" subjects_at_risk="1025"/>
                <counts group_id="E2" events="125" subjects_affected="110" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" events="103" subjects_affected="93" subjects_at_risk="1025"/>
                <counts group_id="E2" events="121" subjects_affected="102" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="95" subjects_affected="70" subjects_at_risk="1025"/>
                <counts group_id="E2" events="79" subjects_affected="67" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="35" subjects_affected="26" subjects_at_risk="1025"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1025"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Glucose urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Hormonal level abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1025"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="1025"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="1025"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1025"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Muscle mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="153" subjects_affected="134" subjects_at_risk="1025"/>
                <counts group_id="E2" events="173" subjects_affected="148" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="56" subjects_affected="52" subjects_at_risk="1025"/>
                <counts group_id="E2" events="46" subjects_affected="45" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1025"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Vomiting in pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Premature rupture of the membranes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Somatoform disorder pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="1025"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="1025"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1025"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1025"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1025"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Genital ulceration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Premenstrual syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Breast discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Coital bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Galacthorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Genital erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Vaginal ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1025"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1025"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Chloasma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Removal of foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1033"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Deese, Principal Investigator</name_or_title>
      <organization>FHI 360</organization>
      <phone>919-544-7040 ext 11292</phone>
      <email>jdeese@fhi360.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

